BBIO

Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027.

Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.

An independent real-world study of 2,684 ATTR-CM patients from U.S. electronic health records found that acoramidis was associated with an 18% lower risk of death, hospitalization, atrial fibrillation, and diuretic intensification compared to tafamidis. Acoramidis showed 27% lower risk of cardiovascular and heart failure hospitalizations. These findings replicate earlier comparative effectiveness analyses and support acoramidis as a preferred stabilizer treatment option.

BridgeBio announced positive Phase 3 CALIBRATE trial results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), showing 91% of participants achieved normal PTH levels compared to 0% on standard care, with 100% reporting symptom improvements versus 46% on conventional therapy. The FDA accepted the NDA with Priority Review (PDUFA date May 8, 2027), and the company initiated the Phase 3 RECLAIM-HP trial for chronic hypoparathyroidism.

BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials.

If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.